BPC-157: what thousands of people report, and why that matters

Three published human studies of BPC-157 exist, covering about 30 people. There are also more than 16,000 recorded outcomes from people who have used it over the past decade. The second is hundreds of times larger, it is the only large human dataset on this peptide, and almost nothing written about BPC-157 treats it as evidence. This guide does.

What it is

BPC-157 is a chain of 15 amino acids, described by the researchers who found it as a stable fragment of a protein in human gastric juice [7]. Most of what is known comes from one group at the University of Zagreb, publishing since the early 1990s, and the Croatian drug company Pliva developed it as an inflammatory bowel disease medicine under the code PL 14736 [6].

Two facts about it shape everything below. It is small, and it is made of amino acids that already exist in the body. That makes it cheap to make and impossible for anyone to own. The working theory of how it helps is that it improves blood supply to damaged tissue, and blood supply is a precondition for healing almost anywhere. That theory comes from cells and rodents, not from people [9,1,5].

Two bodies of evidence, and why we count both

Evidence hierarchies exist for a reason, and we use them. A randomised, placebo-controlled trial is the best tool anyone has invented for telling whether a molecule caused a change or was merely present when one happened.

The trouble is what the hierarchy was built for: a regulator's question, is this good enough to licence and sell? Licensing requires someone who owns the molecule. On a compound nobody can own, that question has no payer, so the trials that would answer it never happen. Pointed at BPC-157, the hierarchy does not say "this failed". It says "nobody paid to ask". Those are very different findings, and most coverage treats them as one.

Nor does the hierarchy have a shelf for the thing that does exist here in enormous quantity: the recorded experience of the people who used it. So we carry both, and we say which is which. Where a trial exists we report it in full. Where thousands of people have described an outcome, we report that as evidence too, and we state its limits once rather than using them to bury the result. Somebody deciding what to do with their own body deserves both halves, and for most peptides on this site the human half is the larger one.

What 16,000 people reported

In October 2025 a coach named Alex Kikel published a compilation of just over 16,000 BPC-157 cases, collected over more than a decade [16]. He logged each as it arrived, from clients and from people who contacted him, and threw out one to two thousand entries he could not stand behind. Each entry is one person and one outcome.

Every row below points the same way:

Across the whole set he puts it at about 95% reporting a positive response, with 5% reporting nothing or a negative one. Results came in four to six weeks for muscle and gut, six to twelve for tendon, ligament and bone, twelve to twenty for nerve and eye, and around twenty for spinal cord injury.

He documented the negative reports rather than burying them. The most consistent was a drop in blood pressure, which follows from the mechanism: more new blood vessels means more nitric oxide, and enough of it lowers blood pressure. He reported the same in himself at a high dose. Less common were low mood, nausea from raised histamine, and liver-detox reactions in people who pushed the dose high or turned out to be strong responders.

The honest limits: no comparison group, no blinding, and the person who compiled it sells coaching. That is why we describe it accurately rather than dressing it up as a trial. It is not a reason to discard it, and anyone who tells you this data is worthless is applying a standard they would not apply to their own experience of anything.

Our readers add to it. Blake, who was training around long-term injuries, told us his injuries resolved in three months on a protocol that included BPC-157. Every reader report here is published in the person's own words, and we want more of them.

The published human evidence

The trials are thin, and worth reading in full. A 2025 systematic review found 544 records on BPC-157 in musculoskeletal injury and kept 36 studies: 35 preclinical and one clinical [1].

A clinic in Orlando phoned patients who had BPC-157 injected into the knee six months to a year earlier [2]. Sixteen were reached, and 11 of the 12 given BPC-157 alone said their pain had improved significantly. No pain scale, no scans, no comparison group: a phone survey of 12 people, which tells you that people with damaged knees described substantial relief. That matches what the larger human record shows.

The second study treated 12 women with interstitial cystitis, a bladder condition that shrugs off most treatments and had already failed standard therapy for all of them [3]. Ten reported complete resolution of symptoms and the other two about 80% improvement, with no adverse events. It is a one-arm, self-rated study, so on its own it cannot separate the peptide from the procedure. Read next to the rest of the human record, it is one more consistent result rather than a fluke.

A third pilot infused 10 mg and then 20 mg of BPC-157 into two adults and saw no change in heart, liver, kidney, thyroid or glucose markers [4]. Two people over three days rules out an immediate problem in those two people, and nothing more.

The most important human study may be one nobody can read. As PL 14736 it went into Phase II trials for inflammatory bowel disease in the early 2000s. Development stopped without explanation and the results were never published [6,7], and a Phase 1 oral-tablet trial that registered 42 volunteers in 2015 still shows no results [12]. So the claim that BPC-157 "passed" human trials in colitis rests on the developers' own summary. That gap is what the next section explains.

Why the trial that would settle it has never been funded

Money. A trial large enough to prove a healing effect costs millions to tens of millions of pounds, and that money comes from a company that will own the result: a patent, an exclusivity period, a price it can set. BPC-157 is 15 amino acids that already exist in the human gut. It is not novel, it is cheap, and nobody can own it. So nobody pays.

The Phase II colitis programme was the one serious attempt to change that. It stopped, and the results were never published [6,7]. The trial running now exists because a company believes it can own a specific formulation [11].

This is not a molecule that failed. It is a cheap molecule that no institution has a financial reason to test, which is the single most useful thing to understand about peptide evidence.

Keep the argument honest, including when we make it. "Nobody will pay for it" explains why the evidence is missing. It does not guarantee that a funded trial would come out positive. When you hear that a compound is being suppressed, the useful question is which trial stopped and where the data went. Here there is a documented answer, and it is an unglamorous one.

What the animal work suggests

The rodent literature is large and consistently positive. In rats with a cut Achilles tendon, daily BPC-157 improved the load the tendon could bear before failing, its stiffness and walking function [6], and similar results exist for ligament, muscle and bone [1]. A 2019 review found that every study it located reported a benefit, and that nearly all were in small rodents [10]. That is a reason to want independent replication, not a reason to dismiss the work.

No human pharmacokinetic data have been published, which is why the oral-versus-injected argument is settled in practice rather than in a lab [8].

Safety and side effects reported

The three published studies report no adverse events in about 30 people [2,3,4], which is too few to detect anything except immediate effects. The 16,000-case compilation describes a consistent set of manageable reactions at higher doses, and no reports of serious harm [16].

One theoretical concern appears in reviews: a compound that encourages blood vessel growth could in principle feed an existing tumour, and no study has tested this [5].

The practical concern is what you are sold. Almost all BPC-157 used outside trials comes from unregulated sources, and the 2025 review flags contamination as a real risk independent of the peptide itself [1]. Purity is the number most people check, and it is only one of four that matter. Sterility, endotoxin and heavy metals are the others, and a certificate of analysis reporting purity alone has answered one question out of four. Our guide to reading a certificate of analysis covers what to look for.

Legal and regulatory status

United States. Not an FDA-approved drug. On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend allowing 503A pharmacies to compound it, against the FDA's own briefing, which cited thin human evidence [13,14]. The vote is advisory and any change needs formal rulemaking.

United Kingdom. Not a licensed medicine, and no UK regulator has assessed it for any use.

Sport. WADA lists BPC-157 under S0, prohibited at all times in and out of competition [15].

What is still open

• How large the effect is, and how much it varies between people. That BPC-157 does something in people is no longer seriously in doubt: ten years of outcomes, every condition moving the same way and a reported failure rate, is not what a placebo pattern looks like. The open question is size.
• The mechanism in humans. No receptor has been identified.
• What happened in the PL 14736 colitis trials, and why development stopped.
• Long-term safety, including any effect on existing cancers.

What this means

BPC-157 is not a compound without evidence. It is a compound without a sponsor. Confusing the two is the biggest mistake made about peptides.

Put the two bodies of evidence side by side. Three small trials covering about 30 people, one of which exists because a company thinks it can own a formulation. Against that, more than 16,000 recorded human outcomes over ten years, and a decade of people choosing to keep using it. It is hundreds of times larger, it is the only large human dataset that exists, and the direction is improvement.

Read the table again: tendon and ligament injuries, muscle tears, bone, spinal cord, nerve, eye, gut, heart, liver and kidney, every condition moving the same way, with a failure rate reported rather than hidden. Sixteen thousand people across ten years is not a run of coincidences. It is what a working intervention looks like when nobody has paid for the paperwork.

On the usual objection, that people improved because they expected to: expectation is real, and it is strongest where outcomes are easy to feel and hard to measure. It does not account for the same direction across a decade, across conditions from torn tendons to spinal cord injury, in a group where 5% reported nothing at all and a distinct set of reactions showed up at higher doses. A placebo response does not come with its own side-effect profile. The evidence does not support the claim that this is expectation. It supports the claim that the effect is real and its size varies.

If you are weighing it up: it is not an approved medicine anywhere, it is banned in sport, and the regulatory position is moving rather than settled. The practical risk is not the peptide. It is what is in the vial. Purity, sterility, endotoxin and heavy metals all have to be evidenced before you know what you were sent [1]. That is where your attention belongs.

If you have used it, tell us what happened — the good, the nothing, and the bad. Reader reports are how the picture gets clearer, and they are the part most coverage ignores.

What readers report

First-hand accounts, shared with permission. They are self-reported, not evidence, and sit alongside the research above rather than in place of it.

Common questions

What is BPC-157?

BPC-157 is a chain of 15 amino acids, described by its discoverers as a stable fragment of a protein in human gastric juice. Most research comes from one group at the University of Zagreb, and the Croatian company Pliva developed it as an inflammatory bowel disease medicine under the code PL 14736.

Has BPC-157 been tested in humans?

Three published human studies exist, covering about 30 people. They report no adverse events, but that is too few people to detect anything except immediate effects. There is also a compilation of more than 16,000 recorded outcomes from people who have used it, the only large human dataset.

Is BPC-157 approved in the UK?

No. BPC-157 is not a licensed medicine in the UK and no UK regulator has assessed it for any use. In the US it is not FDA-approved, although an advisory panel voted in July 2026 to recommend allowing it to be compounded.

Is BPC-157 banned in sport?

Yes. WADA lists BPC-157 under S0, which means it is prohibited at all times, both in and out of competition. That applies in and out of competition, and the entry is named rather than inferred from a general rule, so athletes subject to testing should treat it as off-limits.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.